---
title: "Trends in pregabalin dispensing and overdoses in Australia after media and regulatory actions"
id: "bmj-3-changes-in-pregabalin-use-and-overdose-after-government-interventions-and-media"
canonical_url: "https://medichelpline.com/clinical-feed/bmj-3-changes-in-pregabalin-use-and-overdose-after-government-interventions-and-media"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "BMJ"
source_url: "http://www.bmj.com/content/395/bmj-2026-101021.short?rss=1"
published_at: "2026-11-11T23:30:50.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Trends in pregabalin dispensing and overdoses in Australia after media and regulatory actions
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-3-changes-in-pregabalin-use-and-overdose-after-government-interventions-and-media
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** BMJ
- **Source URL:** [Original Journal Publication](http://www.bmj.com/content/395/bmj-2026-101021.short?rss=1)
- **Published At:** 2026-11-11T23:30:50.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The investigators analysed national dispensing claims (the **PBS** 10% sample) and overdose calls to the New South Wales **Poisons Centre** from January 2016 to December 2024. - They used changepoint analysis, interrupted time series, and latent class analysis to quantify breakpoints, rate ratios, and user clusters; these methods were explicitly reported by the authors. - In the PBS 10% sample, 227,864 people received 3,441,851 pregabalin prescriptions; 4,871 unique pregabalin overdose calls were recorded to the poisons centre during the study period. - Dispensing peaked in 2018, then plateaued and declined; three changepoints in dispensing were detected in December 2018, May 2020, and December 2021. - Combined dispensing rate ratio after breakpoints was 0.748 (95% CI 0.700 to 0.800), equivalent to an estimated 118,390 (93,960 to 140,940) fewer national prescriptions by December 2021 and a monthly ongoing reduction of 0.7% (0.5% to 0.9%). - All three breakpoints coincided with declines in overdose rates; the combined overdose rate ratio was 0.532 (95% CI 0.406 to 0.695), equivalent to about 41.3 (26.9 to 52.4) fewer overdose calls in December 2021 and a monthly reduction of 1.6% (1.0% to 2.3%). - Latent class analysis of 57,744 people dispensed pregabalin in the 12 months after the final breakpoint identified four clusters; a high risk group (7,790, 13.5%) was younger, more often male, dispensed larger quantities with shorter refill intervals, and had high co-use of opioids and benzodiazepines (65.7% and 31.5% respectively among that group). - The authors linked major decreases in use and overdose temporally to late 2018 media coverage, May 2020 prescribing and dispensing restrictions, and a December 2021 breakpoint that may reflect delayed effects of boxed warnings implemented in February 2021. - The dataset definitions, inclusion criteria (PBS codes for capsule strengths and Poisons Centre coding of intentional exposures), and analytic approaches were reported in the article; specific model parameters beyond those reported in results were not provided in the source excerpt. - The study provides population-level observations suggesting regulatory and communications measures coincided with reduced **pregabalin** prescribing and harms; causal inference beyond temporal association was not claimed by the authors in the reported text.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#main-content) Intended for healthcare professionals * [Subscribe](https://www.bmj.com/us/subscribe) * [ My Account ](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1) * [My email alerts](https://myaccount.bmj.com/myaccount/account/hw-registration.html) * [BMA member login](https://bmjverification.bma.org.uk/validate/userdetails?url=https://www.bmj.com/content/395/bmj-2026-101021?rss=1&variant=short&sso=) [ Login ](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1) * Username * Password * [Forgot your log in details?](https://www.bmj.com/user/password "Retrieve your credentials.") [Need to activate](https://journals.bmj.com/cgi/activate/basic) * * * [BMA Member Log In](https://bmjverification.bma.org.uk/validate/userdetails?url=https%3A//www.bmj.com/content/395/bmj-2026-101021%3Frss%3D1%26variant%3Dshort%26sso%3D "Log in here if you are a BMA member.") [Log in via OpenAthens](https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&subcode=bmjjournals&hw-shib-return-uri=https%253A%252F%252Fwww.bmj.com%252Fcontent%252F395%252Fbmj-2026-101021.short%253Frss%253D1) [Log in via your institution](https://www.bmj.com/login/shibboleth?uri=https%3A%2F%2Fwww.bmj.com%2Fcontent%2F395%2Fbmj-2026-101021%3Frss%3D1&subcode=bmjjournals&env=prod) Edition: [ US ](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1) * [UK](https://www.bmj.com/bmj_countries/switch/uk?destination=node/1130024%3Frss%3D1%26variant%3Dshort) * [South Asia](https://www.bmj.com/bmj_countries/switch/india?destination=node/1130024%3Frss%3D1%26variant%3Dshort) * [International](https://www.bmj.com/bmj_countries/switch/international?destination=node/1130024%3Frss%3D1%26variant%3Dshort) [Our company](https://www.bmj.com/company?int_source=tbmj&int_medium=header&int_campaign=URLswitch) [ Toggle navigation ](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1) [ The BMJ logo ](https://www.bmj.com/ "Home") [Site map](https://www.bmj.com/sitemap) [Search](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1 "Search") ## Search form Search Search * [Advanced search](https://www.bmj.com/search/advanced "Advanced search") * [Search responses](https://www.bmj.com/rapid-responses "Search responses") * [Search blogs](https://blogs.bmj.com/bmj/ "Search blogs") [ Toggle top menu ](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1) * [Research](https://www.bmj.com/us/research) * [At a glance](https://www.bmj.com/us/research) * [Research papers](https://www.bmj.com/us/research/research) * [Research methods and reporting](https://www.bmj.com/us/research/research%20methods%20%26amp%3B%20reporting) * [Minerva](https://www.bmj.com/us/research/minerva) * [Education](https://www.bmj.com/us/education) * [At a glance](https://www.bmj.com/us/education) * [Clinical reviews](https://www.bmj.com/us/education/clinical%20review) * [Practice](https://www.bmj.com/us/education/practice) * [Minerva](https://www.bmj.com/us/education/minerva) * [Endgames](https://www.bmj.com/us/education/endgames) * [State of the art](https://www.bmj.com/specialties/state-art) * [What your patient is thinking](https://www.bmj.com/specialties/what-your-patient-thinking) * [Rapid recommendations](https://www.bmj.com/rapid-recommendations) * [Student](https://www.bmj.com/student) * [News & Views](https://www.bmj.com/us/news) * [At a glance](https://www.bmj.com/us/news) * [News](https://www.bmj.com/us/news/news?category=News) * [Features](https://www.bmj.com/us/news/feature) * [Editorials](https://www.bmj.com/us/news/editorial) * [Analysis](https://www.bmj.com/us/news/analysis) * [Opinion](https://www.bmj.com/news/opinion) * [Head to head](https://www.bmj.com/us/news/head%20to%20head) * [Editor's choice](https://www.bmj.com/us/news/editor%27s%20choice) * [Letters](https://www.bmj.com/us/news/letter) * [Obituaries](https://www.bmj.com/us/news/obituary) * [Careers](https://www.bmj.com/careers-articles) * [Rapid responses](https://www.bmj.com/rapid-responses) * [Campaigns](https://www.bmj.com/campaigns) * [At a glance](https://www.bmj.com/campaigns) * [Better evidence](https://www.bmj.com/better-evidence) * [Climate change](https://www.bmj.com/campaign/climate-emergency) * [Divestment from fossil fuels](https://www.bmj.com/divestment) * [Patient and public partnership](https://www.bmj.com/campaign/patient-partnership) * [Too much medicine](https://www.bmj.com/too-much-medicine) * [Wellbeing](https://www.bmj.com/wellbeing) * [The BMJ Collections](https://www.bmj.com/content/bmj-collections) * [Jobs](https://www.bmj.com/careers) * [Doctor Jobs UK](https://www.bmj.com/careers) * [Hospital Jobs UK](https://www.bmj.com/careers/jobs/hospital/) * [GP Jobs UK](https://www.bmj.com/careers/jobs/general-practice/) * [International Jobs](https://www.bmj.com/careers/jobs/international/) * [Archive](https://www.bmj.com/archive) * [For authors](https://www.bmj.com/about-bmj/resources-authors) * [Hosted](http://hosted.bmj.com) 1. [Research](https://www.bmj.com/us/research) 2. Changes in pregabalin... 3. Changes in pregabalin use and overdose after government interventions and media coverage: retrospective observational study CCBY Open access Research # Changes in pregabalin use and overdose after government interventions and media coverage: retrospective observational study BMJ 2026; 395 doi: (Published 11 November 2026) Cite this as: BMJ 2026;395:e101021 ## [Linked Editorial Pregabalin: the case for dialling back on a mediocre analgesic ](https://www.bmj.com/content/395/bmj-2026-101357) * [Article](https://www.bmj.com/content/395/bmj-2026-101021 "Article Tab - Article")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_art/node:1130024/1 "Article Tab - Article") * [Related content](https://www.bmj.com/content/395/bmj-2026-101021/related "Article Tab - Related Articles")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_related_art/node:1130024/1 "Article Tab - Related Articles") * [Metrics](https://www.bmj.com/content/395/bmj-2026-101021/article-info "Article Tab - Info & Metrics")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_info/node:1130024/1 "Article Tab - Info & Metrics") * [Responses](https://www.bmj.com/content/395/bmj-2026-101021/rapid-responses "BMJ Article Related Rapid Responses")[](https://www.bmj.com/panels_ajax_tab/bmj_related_rapid_responses/node:1130024/1 "BMJ Article Related Rapid Responses") * [Peer review](https://www.bmj.com/content/395/bmj-2026-101021/peer-review "Article Tab - Peer review")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_peer_review/node:1130024/1 "Article Tab - Peer review") * [](https://www.bmj.com/content/395/bmj-2026-101021/submit-a-rapid-response "BMJ Rapid Responses Form")[](https://www.bmj.com/panels_ajax_tab/bmj_rapid_responses_form/node:1130024/1 "BMJ Rapid Responses Form") ![Loading](https://www.bmj.com/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) 1. Rose Cairns[![](https://www.bmj.com/sites/default/themes/bmj/the_bmj/img/vector_iD_icon.svg)](https://orcid.org/0000-0002-8946-5079)[1](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-1)[2](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-2), associate professor, 2. Firouzeh Noghrehchi[![](https://www.bmj.com/sites/default/themes/bmj/the_bmj/img/vector_iD_icon.svg)](https://orcid.org/0000-0003-2263-2108)[1](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-1), research fellow biostatistics, 3. Sallie-Anne Pearson[![](https://www.bmj.com/sites/default/themes/bmj/the_bmj/img/vector_iD_icon.svg)](https://orcid.org/0000-0001-7137-6855)[3](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-3), professor of health systems, 4. Andrea L Schaffer[![](https://www.bmj.com/sites/default/themes/bmj/the_bmj/img/vector_iD_icon.svg)](https://orcid.org/0000-0002-3701-4997)[4](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-4), senior epidemiologist, 5. Jonathan Brett[![](https://www.bmj.com/sites/default/themes/bmj/the_bmj/img/vector_iD_icon.svg)](https://orcid.org/0000-0003-3065-7495)[3](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-3)[5](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-5), senior research fellow, 6. Nicholas A Buckley[![](https://www.bmj.com/sites/default/themes/bmj/the_bmj/img/vector_iD_icon.svg)](https://orcid.org/0000-0002-6326-4711)[1](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-1)[2](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#aff-2), professor of clinical pharmacology and toxicology [Author affiliations](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1) 1. 1School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia 2. 2New South Wales Poisons Information Centre, The Children’s Hospital at Westmead, Westmead, Australia 3. 3Medicines Intelligence Research Program, Faculty of Medicine & Health, UNSW Sydney, Australia 4. 4Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK 5. 5St Vincent’s Hospital Sydney, Sydney, Australia 1. Correspondence to: R Cairns rose.cairns@sydney.edu.au (@RoseFJCairns on X) * Accepted 6 October 2026 ## Abstract **Objectives** To evaluate trends in pregabalin use and overdose in Australia and examine temporal relationships with media coverage (December 2018), prescribing and dispensing restrictions (April 2020), and boxed warnings (February 2021). **Design** Retrospective observational study of dispensing and overdose data, with changepoint, interrupted time series, and latent class analysis. **Setting and participants** Pharmaceutical Benefits Scheme data (PBS; 10% random sample of people with drug subsidies) and overdose calls (self-harm, recreational use, and misuse) reported to Australia’s largest Poisons Centre (50% national sample), 2016-24. **Main outcome measures** Population adjusted rates of dispensing and overdose, timing of breakpoints and rate ratios, proportion of people who use pregabalin at high risk of misuse. **Results** 227 864 people were dispensed 3 441 851 pregabalin prescriptions in the PBS 10% sample and 4871 pregabalin overdose calls were made to the Poisons Centre. Pregabalin use peaked in 2018 before plateauing and declining. Three breakpoints were found in dispensing data, with major decreases in level and slope: December 2018, May 2020, December 2021. The combined rate ratio for dispensing was 0.748 (95% confidence interval 0.700 to 0.800). Compared with the projected historical trend in the absence of interventions (counterfactual), approximately 118 390 (93 960 to 140 940) fewer pregabalin prescriptions were recorded nationally in December 2021, and an ongoing reduction of 0.7% (0.5% to 0.9%) was found each month. All breakpoints were associated with declines in overdose rates, with a combined rate ratio of 0.532 (95% CI 0.406 to 0.695). This reduction corresponded to approximately 41.3 (26.9 to 52.4) fewer pregabalin overdose calls in December 2021 and an ongoing reduction of 1.6% (1.0% to 2.3%) each month. Latent class analysis of 57 744 people dispensed pregabalin in the 12 months after the final breakpoint revealed four groups. The high risk group (7790, 13.5%) were more likely male, younger, dispensed more pregabalin, with shorter refill interval and high rates of opioids and benzodiazepine co-use (5120 (65.7%) and 2455 (31.5%), respectively). **Conclusions** Pregabalin use and overdose in Australia have declined in recent years. Major decreases in trend corresponded with media coverage (December 2018) and prescribing and dispensing restrictions (May 2020). The third breakpoint may be a delayed impact of boxed warnings (implemented February 2021). These findings suggest that regulatory and risk communication measures may contribute to reducing pregabalin related harm. ## Introduction Gabapentinoids (pregabalin and gabapentin) were originally developed as antiseizure drugs. Subsequently licenced indications expanded to include neuropathic pain, fibromyalgia, and generalised anxiety disorder, depending on the country. Despite this relatively narrow range of approved indications, gabapentinoids are considered “blockbuster” drugs.[1](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-1) High income countries have the highest rates of gabapentinoid consumption, while low and middle income countries have had the highest consumption growth in recent years.[2](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-2)[3](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-3) Most of this consumption is driven by off label use for non-registered indications.[4](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-4)[5](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-5)[6](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-6) Alongside rising use, there is mounting evidence of misuse, dependence, and harms from gabapentinoid use in Europe, the United States, Asia, and Australia.[7](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-7)[8](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-8) In the UK, one third of substance use deaths involve a gabapentinoid, predominantly pregabalin,[9](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-9) and deaths involving gabapentinoids have more than doubled from 2018 to 2022.[10](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-10) Similar concerns have been reported elsewhere—misuse has increased in France, where over one quarter of falsified prescriptions involve pregabalin.[11](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-11) In Australia, pregabalin overdose increased by 54% year-on-year between 2005 and 2016, mirroring increased use after its government subsidy,[12](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-12)[13](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-13) and around 15% of people dispensed pregabalin were at high risk of misuse.[12](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-12) In Australia, several strategies have been implemented in response to concerns over pregabalin related harm. The Therapeutic Goods Administration (Australia’s drugs regulator) launched an investigation into pregabalin misuse in 2019,[14](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-14) resulting in alerts to healthcare professionals and updates to manufacturer product information in February 2021. The Therapeutic Goods Administration mandated a black box warning on pregabalin relating to its misuse potential, and highlighting risks of concomitant use with benzodiazepines and opioids,[15](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-15) consistent with action taken by other countries.[16](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-16) At a state level, in New South Wales (Australia’s most populous state), pregabalin was upscheduled to schedule 4 appendix D (S4D, prescribed restricted substances), placing it under stricter controls that are consistent with benzodiazepines and weak opioids. This introduced requirements for secure storage in pharmacy safes and tighter regulation on possession and supply. Additionally, real time prescription monitoring was introduced in New South Wales from November 2021, becoming fully operational in May 2022.[17](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-17) Beyond regulatory measures, prescriber and consumer behaviour can also be influenced by media coverage.[18](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-18) Following research publications,[12](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-12)[13](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-13) several high profile stories highlighted harms from pregabalin in the Australian press in late 2018,[19](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-19)[20](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-20) resulting in national journalism awards.[21](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-21) This study aims to provide an update on pregabalin use and misuse in Australia. We have focused on pregabalin because rates of gabapentin use and harms in Australia are low.[12](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-12) Specifically, we aimed to quantify trends in dispensing and poisoning over time, and examine temporal changes relating to key policy and media events described above; identify and characterise clusters of people who use pregabalin based on personal and drug use characteristics; and identify trends in clusters and prevalence of high risk use as defined by concomitant use of opioids and benzodiazepines, dose dispensed, dispensing interval, and number of prescribers. **Methods** ### Data sources and study design This is a retrospective study of pregabalin dispensing and overdose data from January 2016 to December 2024 (inclusive). We quantified medicine use based on Pharmaceutical Benefits Scheme (PBS) dispensing claims. Australia has a universal healthcare system where citizens and permanent residents are permitted to access subsidised drugs through the PBS. The PBS 10% sample is a national dataset containing a random 10% sample of any Australian ever dispensed a PBS drug and their dispensing history. People in the PBS dataset receive a randomly assigned unique identifier and the 10% sample is selected based on the last digit of each person’s unique identifier. There are two categories of beneficiaries: general beneficiaries who pay a higher copayment than their concessional beneficiary counterparts. People entitled to concessional benefits are generally aged 65 years and older, on low incomes, unemployed, or with disabilities. This dataset is described in detail elsewhere.[22](https://www.bmj.com/content/395/bmj-2026-101021.short?rss=1#ref-22) These nationwide, person level dispensing data allowed us to classify people who use pregabalin into clusters based on demographic and drug use characteristics (eg, dose, dispensing interval, number of prescribers, and use with other drugs). We included all pregabalin dispensings in the PBS 10% sample using PBS codes 2348N (25 mg capsules), 2335X (75 mg capsules), 2355Y (150 mg capsules), and 2363J (300 mg capsules); all are available in a standard pack size of 56 capsules. We quantified pregabalin overdose using data from the New South Wales (NSW) Poisons Information Centre. The NSW Poisons Information Centre is Australia’s largest poisons centre, taking approximately 50% of Australia’s 240 000 poisoning calls, 65% of which originate from the state of NSW. The Poisons Information Centre provides poisoning management advice to healthcare professionals and members of the public. The NSW Poisons Information Centre codes drug use with a substance dropdown list and there is a specific code for pregabalin. We included intentional pregabalin poisonings (which includes recreational use, self-harm overdose, and other forms of intentional non-medical use). Unique overdose calls were included, with follow-up calls about the same person excluded from counts. Because of several possible impacts on pregabalin use (described above), our primary analysis was a changepoint analysis using monthly population adjusted dispensing rates. The changepoint analysis is a data d
## Related Clinical Research

- [Exercise Dose and Depression in Lung Cancer: Meta-analysis Finds Benefit at ~602 MET-min/week](https://medichelpline.com/clinical-feed/pubmed-43064838.md) (DOI: 10.1007/s00520-026-11497-x)
- [Preparation–need concordance and patient readiness in robot-assisted surgery: scoping review findi](https://medichelpline.com/clinical-feed/pubmed-43064872.md) (DOI: 10.1007/s11701-026-04217-4)
- [Aripiprazole blocks sex-dependent nicotine reward in mice, preprint reports](https://medichelpline.com/clinical-feed/biorxiv-3-sex-dependent-rewarding-effects-of-nicotine-in-mice-are-prevented-by-the.md)
- [Topiramate target genetics suggest reduced binge-eating risk via CA4 inhibition](https://medichelpline.com/clinical-feed/medrxiv-19-investigating-the-potential-effect-of-topiramate-on-anorexia-nervosa-and-binge.md)
- [Real-world Use and Reported Harms of BPC-157 and TB-500 for Musculoskeletal Injury](https://medichelpline.com/clinical-feed/medrxiv-10-real-world-use-dosing-and-reported-side-effects-of-bpc-157-and-tb-500-for.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.